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A B S T R A C T
Purpose: The aim of this studywas to examine the potential effects of valproate (VPA) and oxcarbazepine
(OXC) on testicular development in rats.
Methods: Forty-two Wistar rats were randomly divided into three groups of 14 rats each. Each group
received the following via gavage over 90 days: group 1, tap water (control group); group 2, VPA
(300 mg/kg/day); group 3, OXC (100 mg/kg/day). After sacriﬁce, body, testicular and epididymidis
weights were measured. Testes were sampled, ﬁxed and processed, and quantitative morphometric
analysis of Sertoli cells, spermatocytes and spermatids was performed in stages II, V and XII by
histopathological examination. Immunohistochemical staining was performed to transform growth
factor beta 1 (TGF-b1) and p53, and the apoptotic index was assessed using the TUNEL method.
Results: Testis and relative testis weights were signiﬁcantly lower in the VPA group compared to the
control group (p < 0.05). Spermatogonia, pachytene spermatocyte and round spermatocyte numbers
decreased in all stages in both the VPA and OXC groups compared to the control group, though this was
not statistically signiﬁcant (p > 0.05). Apoptotic cell counts and p53 immunoreaction were signiﬁcantly
high and TGF-b1 expression was signiﬁcantly lower in the VPA group compared to that of the control
group (p < 0.05). In the OXC group, p53 immunoreaction and TGF-b1 expression decreased compared to
the control group, but this difference did not attain statistical signiﬁcance (p > 0.05).
Conclusions: Our results show that VPA treatment from prepuberty to adulthood signiﬁcantly negatively
affects spermatogenesis, not only by reducing testicular weight, but also by increasing apoptotic death
and p53 and decreasing TGF-b1 activation. OXC has a minimal side effect on testicular development.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Valproate (VPA) is a major antiepileptic drug with a broad
spectrum of antiepileptic activity used in both adults and
children.1,2 However, there is increasing concern about the
possible effects of VPA on reproductive endocrine function.3 These
include testicular atrophy, reduced or absent spermatogenesis and
atrophy of the prostate, epididymis and seminal vesicles.4–8 VPA* Corresponding author. Tel.: +90 462 377 59 21; fax: +90 462 325 05 18.
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doi:10.1016/j.seizure.2010.11.019seems to affect the male reproductive system in a dose-dependent
manner.9 In agreement with a number of prior studies, one recent
piece of research demonstrated that a dose of 400 mg/kg/day VPA
was associated with testicular atrophy and histologically veriﬁed
spermatogenetic arrest in male rats, while 200 mg/kg/day was
not.9 These animal studies on the effect of VPA on the reproductive
and neuroendocrine system have largely focused on adult rats,
although VPA is widely used for children as well as adults with
epilepsy.10
Oxcarbazepine (OXC) is a newer antiepileptic agent that has
recently become increasingly used for childhood epilepsies.11
There are few studies on the reproductive and endocrine effects of
OXC in the literature.3 One study demonstrated that after the
replacement of carbamazepine (CBZ) with OXC, CBZ-induced
alterations in the reproductive endocrine hormones in menvier Ltd. All rights reserved.
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OXC monotherapy were associated with reproductive endocrine
hormone abnormalities.13 Sperm abnormalities have also been
reported among men on OXC.8 To the best of our knowledge, there
have been no previous animal studies on the effects of OXC on
testis morphology.
Animal studies have three main advantages over human
studies. They allow the investigation of the independent effects
of the epilepsy itself and the effects of AEDs in isolation and permit
the examination of gonadal morphology.14 Our aim was to deﬁne
the morphological effects of VPA and OXC, two antiepileptics
widely used during childhood, on the rat testis. The results will
provide important clues as to the reproductive effect of chronic use
of these antiepileptics from childhood to adulthood in boys with
epilepsy.
2. Materials and methods
2.1. Animals
Forty-two prepubertal male Wistar rats (age 21–24 days and
weighing between 49.5 and 58.7 (g)) from the Gazi University
Medical Faculty animal laboratory were used in this experimental
study. All animals were housed in groups in plastic cages at
constant room temperature (21–22 8C) in a 12 h-light/dark cycle
(lights on at 07:00 a.m.). There were no speciﬁc restrictions
regarding diet contents or quantities. Rats in all groups were given
free access to food and water. Standard rat chow as routinely
provided in the Gazi University Animal Experiments Laboratory
was used. Feeding was performed under control conditions by
veterinarians in the laboratory. The control and drug-administered
groups consumed the same chow.
All animal experiments were carried out in accordance with the
European Communities Council Directive of 24 November 1986
(86/609/EEC) and were approved by the Gazi University Animal
Care Committee.
2.2. Experimental procedure and dosing
Rats were divided into three experimental groups of 14 animals
each. Group 1 (control group) was administered tap water via
gavage, group 2 (VPA group)was administered 300 mg/kg/day VPA
(Depakin1 200 mg/1000 ml solution, Sanoﬁ Dogu, Istanbul,
Turkey), and group 3 (OXC group) was administered 100 mg/kg/
day OXC (Trileptal1 60 mg/1000 ml solution, Novartis, Istanbul,
Turkey). Ordinary drinking water was used as the control solution.
Dosages of drugs in treatment groups 2 and 3 were determined
according to rat weights. Under this regimen, a rat weighing 100 g
in group 2 received 30 mg VPA based on a dose of 300 mg/kg/day,
and a rat weighing 100 g in group 3 received 10 mg OXC based on a
dose of 100 mg/kg/day. VPA solution at a concentration of 200 mg/
1000 ml and 170 ml of OXC solution at a concentration of 60 mg/
1000 ml were administered.
The VPA dose was adopted from a previous study by Røste
et al.15 An antiepileptic dose of OXC of 30 mg/kg has been proposed
in the literature for single use, and higher for chronic use.16 We
used the higher dose of 100 mg/kg/day. All drugs were adminis-
tered orally for 90 days at 12-h intervals in two separate doses via
gavage prepared by bending the tip of themetal tube and coating it
with silicone. During the study period, two rats in group 1, four rats
in group 2, and three rats in group 3 were eliminated or lost for
various reasons (mainly due to disease and death).
Rats were weighed and sacriﬁced 12–16 h after the ﬁnal drug
administration by taking 6–8 ml intracardiac blood under anes-
thesia. The right and left testes were removed, weighed and ﬁxed
in 10% formalin for histological examination. The absolutetesticular and epididymidis values were the weight of the organ
on a sensitive scale. Relative weight was the ratio of absolute
testicular weight to body weight. Four mm-thick tissue sections
were stained with hematoxylin-eosin. Morphological descriptions
of rat spermatogenetic cells and stages were used as a guide, while
the quantitative analysis of spermatogenetic cells was performed
as described in previous studies.17–22 Each slide was analyzed for
three selected stages of the spermatogenic cycle (stages II, V and
XII). For each stage, three separate seminiferous tubules were
randomly selected and total cell count in these was assessed for
spermatogonia, pachytene spermatocytes, zygotene spermato-
cytes, round spermatids and Sertoli cells. Relevant cells speciﬁc to
each stage were included17 and the ratio of spermatogenetic cells
to Sertoli cells calculated.
Indirect immunohistochemical staining (using p53 and TGF-b1
primary antibodies) and evaluation of apoptosis (TUNEL) were
performed on 5mm-thick parafﬁn tissue sections after 24–28 h.
One hundred serial sections from each testis were taken and every
10th, 20th, 30th, 40th, 50th, 60th, 70th, 80th, 90th and 100th slide
chosen. These procedures were repeated for every single dye.
2.3. Biochemical assays
Blood samples were centrifuged for 10 min at 2500 rpm. Serum
was removed and stored at 80 8C until measurement. Serum
concentrations of monohydroxycarbamazepine (OXC active me-
tabolite) were assessed using high performance liquid chromatog-
raphy (HPLC). VPA levels were measured using the ﬂuorescence
polarization method in a Roche Cobas Integra 400 Analyzer and
expressed as mg/ml.
2.4. Determination of apoptosis
The terminal deoxynucleotidyl-transferase-mediated dUTP-
biotin nick end labeling (TUNEL) staining method was employed
to determine apoptotic cell numbers. Testis sections were stained
using an in situ cell death detection kit (ApopTag Plus Peroxidase In
Situ S7101, Lot: 0603025277). Slices 5 mm in thickness were
prepared from the parafﬁn blocks with an automated microtome
device. Slides were incubated overnight at 60 8C. Sections were
deparafﬁnized in xylene for 1 h and rehydrated with reduced
alcohol series (100%, 95%, 85%, 70% and 60%). They were then
incubated with 20 mg/ml proteinase K for 10 min. Washing with
phosphate-buffered saline (PBS) at pH 7.4 was performed at each
stage. Endogenous peroxidase activity was blocked with 3% H2O2.
After washing with PBS, sections were incubated with equilibra-
tion buffer for 10–15 min and TdT enzyme (77 ml reaction
buffer + 33 ml TdT enzyme mix, 1 ml TdT enzyme) for 60 min at
37 8C. Working strength stop/wash buffer (1:10) was applied for
10 min at room temperature and slices were incubated with anti-
digoxigenin conjugate for 30 min. After washing with PBS three
times for 5 min, the sectionswere stainedwith DAB components to
reveal TUNEL-positive cells and were counterstained with Methyl
green. Histopathological signs and TUNEL-positive cells were
evaluated by two independent observers blind to the study groups.
2.5. Immunohistochemical evaluation
Tissue samples from each group were ﬁxed in neutral formalin
for 72 h and processed for parafﬁn embedding. Sections 4–5 mm
thick were processed for polylysine microscope slides. For
immunohistochemical examination, the slides were stored in a
microwave oven in a 0.01 M citrate buffer (Lot: 90030610D, Cat:
AP-9003-500, LabVision, Fremont, CA, USA). Endogenous peroxi-
dase activity was blocked in 3% hydrogen peroxide (Lot:
AHP40114, Cat: TA-125-HP, LabVision, Fremont, CA, USA). Epitopes
Table 1
The body weight, testis weight and relative testis weight of rats treated with control solution, VPA and OXC, during 90 days.
Control (n=12) VPA (n=10) OXC (n=11)
Body weight (g) 213.5014.15 226.6010.70 212.3015.27
Testis weight (mg) 2.32 0.24 2.040.17a 2.280.25
Relative testis weight (mg/g body weight) 0.006 0.0007 0.0040.0004b 0.0050.007
Epididymides weight (mg) 0.87 0.10 0.790.10 0.850.08
VPA, valproate; OXC, oxcarbazepine. Data were presented as mean standard deviation.
a p<0.01 vs. control group.
b p<0.001 vs. control group.
Table 2
The ratios of spermatogonia/Sertoli cells, pachytene spermatocytes/Sertoli cells and
round spermatocytes/Sertoli cells in stage II, V and XII.
Stage II Stage V Stage XII
Spermatogonia/Sertoli cells
Control (n=12) 1.581.07 2.400.54 2.000.71
VPA (n=10) 1.19 0.58 2.270.51 1.89 0.84
OXC (n=11) 1.53 0.30 2.190.73 1.57 0.67
p >0.05 >0.05 >0.05
Pachytene spermatocytes/Sertoli cells
Control (n=12) 3.471.74 4.030.68 1.28 0.52
VPA (n=10) 2.45 0.69 3.490.94 0.93 0.26
OXC (n=11) 3.401.61 3.540.87 1.15 0.45
p >0.05 >0.05 >0.05
Round spermatocytes/Sertoli cells
Control (n=12) 11.094.09 10.161.52 4.31 0.83
VPA (n=10) 9.122.66 8.872.49 3.55 0.42
OXC (n=11) 10.134.47 9.381.44 3.88 0.78
p >0.05 >0.05 >0.05
VPA, valproate; OXC, oxcarbazepine. Data were presented as mean standard
deviation. Group vs. control; p> 0.05.
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85-9043, Zymed, South San Francisco, USA) and ﬁve groups were
then prepared from each slide. The ﬁrst group was incubated with
p53 (FL-93) (Rabbit Polyclonal IgG, Lot: A1806, Cat: SC-6243, Santa
Cruz Biotechnology, CA, USA) and the second with transforming
growth factor beta1 (TGF-b1) (v) (Rabbit Polyclonal IgG, Lot:A1306,
Cat: SC-146, Santa Cruz Biotechnology, California, USA) then diluted
in UltraAb Diluent (Lot: 50481612, Cat: 00-3118, Zymed, South San
Francisco, USA) for 60 min at room temperature. After incubation,
the secondary antibody (Broad spectrum Histostain Plus, Lot:
41080981, Cot: 85-9043, Zymed, South San Francisco, USA) was
applied. We then used 3-amino-9-ethylcarbazole (AEC) (Lot:
50481594, Cat: 00-2007, Zymed, South San Francisco, USA) for
TGF-b1 antibodies and 3,3-diaminobenzidine tetrahydrochloride
(DAB) (Lot: 40980870, Cat: 00-2020 Zymed, South San Francisco,
USA) as chromogen for p53 antibodies. Slides were next counter-
stainedwithMayer’s hematoxylin and examined under anOlympus
BH2 photo-light microscope. Serial sections were examined and
immunolabeling patterns compared. Two observers blind to the
samples evaluated the immunolabeling scores. Labeling intensity
was graded semi-quantitatively and HSCOREs calculated using the
equationHSCORE =
P
Pi (i + 1), where i = intensity of labelingwith a
value of 1, 2 or 3 (weak, moderate, or strong, respectively) and Pi is
the percentage of labeled spermatogenic cells for each intensity,
varying from 0% to 100%.23
2.6. Statistical analysis
Data were analyzed using SPSS. All data are expressed as
means  standard deviation. Comparisons between groups were
tested using ANOVA or Kruskal–Wallis variance analysis followed by
Tukey’s multiple comparison test or the Mann-Whitney U test.
Statistical signiﬁcance was set at p < 0.05.
3. Results
Serum levels of antiepileptics were 23.74  6.19 mg/ml for the
VPA group and 2.08  0.65 mg/ml for the OXC group.
Body and epididymidis weights were higher in the VPA group
compared to the control and OXC groups, but these changes were
not statistically signiﬁcant (p > 0.05). Testis weights and relative[()TD$FIG]
Fig. 1. Apoptosis in spermatogoniumwith TUNEL staining. Seminiferous tubules of the co
400, inset: ( [TD$INLINE] ) TUNEL-positive spermatogonium cells at 100 TUNEL staining.testis weights in the VPA group were signiﬁcantly lower compared
to the control group (p = 0.007 and p = 0.001, respectively). There
was no signiﬁcant change in testis weights in the OXC group
(p > 0.05). Body weights and the absolute and relative testicular
and epididymidis weights of the controls and VPA and OXC groups
undergoing 90 days of treatment are presented in Table 1.
There was no necrosis, obvious depletion, disorganization or
exfoliation of germ cells, tubular atrophy, inﬂammatory reaction or
apparent pathological alteration in the Leydig cells in any of the
slides examined. Sertoli cells were analyzed and counted in all the
tubules evaluated. No vacuolation, swelling or cytoplasmics
apoptotic bodies or phagocytized spermatogenic cells were
observed in the Sertoli cells.
The ratio of spermatogonia, pachytene spermatocytes and
round spermatocytes to Sertoli cells in stages II, V and XII,
decreased in both the VPA and OXC groups, though this was not
statistically signiﬁcant (p > 0.05) (Table 2).
Apoptotic cell counts in the VPA group were higher than those
in the control group (p < 0.0001) (Fig. 1 and Table 3). The OXC
group exhibited no signiﬁcant difference in apoptotic countntrol (A), VPA (B) and OXC groups (C) ( [TD$INLINE] ): TUNEL-positive spermatogonium cells at
Table 3
The apoptotic cell counts, p53 and TGF-b1 expression in control, VPA and OXC
groups.
Control (n=12) VPA (n=10) OXC (n=11)
Apoptotic cell counts 151.2 20.21.5b 16.21.3
p53 60.99.6 90.615.3b 74.314.0
TGF-b1 10010.3 80.417.0a 86.45.4
VPA, valproic acid; OXC, oxcarbazepine; TGF-b1, transforming growth factor beta 1.
Data were presented as mean standard deviation.
a p<0.05 vs. control group.
b p<0.0001 vs. control group.
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group was similar to the control group and signiﬁcantly increased
in the VPA group compared to the controls (p < 0.0001) (Table 3).
TGF-b1 expression was observed in a signiﬁcantly lower number
of cells in the VPA group than in the control group (p < 0.05). Mild
to moderate immunoreactivity was observed in the OXC group
(Fig. 2 and Table 3).
4. Discussion
In this study, we determined the morphological effects of VPA
and OXC, two antiepileptics widely used during childhood, on the
rat testis. While we established no signiﬁcant effect of OXC on
testis development up to adulthood, VPA use had signiﬁcant
effects.
The toxicological effects of VPA on testis of rats appear to be
dose- and duration-related.9,7 Nishimura et al.7 reported sperma-
togenetic abnormalities after 4, 7 and 10 days of 500 mg/kg of VPA,
the 10-day group exhibiting decreased testis weight. No abnor-
malitywas seen in similar groups at a 250 mg/kg dosage. Testicular
atrophywas observed inWistar rats following 90-day treatment at
400 mg/kg, but not after 200 mg/kg.9 Much higher doses resulted
in testicular atrophy in rats in earlier studies.5 The 300 mg/kg dose
in our study lay between the two doses used by Røste et al.9 and
resulted in decreasing testicular weight but no abnormal
spermatogenesis. Rats’ ages at the beginning of this research
were 21–24 days, much younger than those in Røste et al.’s study.9
We therefore speculate that a 300 mg kg/dose may be toxic at
younger ages but not at older ones. Since only a single dose was
used in this study, no information was obtained regarding the
dose-dependent reproductive effects of VPA.
In our study, in contrast to VPA, OXC gave rise to no signiﬁcant
change in either testis or epididymis weight. To the best of our
knowledge, this is the ﬁrst animal study to focus on the
reproductive effects of OXC in male subjects. Mikkonen et al.24
showed that OXC is not associated with changes in mean testicular
volumes in boys and young men with epilepsy. Isoja¨rvi et al.8
similarly indicated that OXC did not cause a signiﬁcant testis
volume change, but they reported that it did lead to sperm
abnormalities. We did not examined sperm abnormalities in this
[()TD$FIG]
Fig. 2. TGF-b1 immunoreactivity of the primary spermatocyte in seminiferous tubules. T
OXC group (C). ( [TD$INLINE] ): 400.study, but, in parallel with the literature, OXC caused neither
testicular atrophy nor spermatogenetic arrest.
Except for minimal VPA-associated decreases in cell diameters,
there was no necrosis, obvious depletion, disorganization or
exfoliation of germ cells, tubular atrophy, inﬂammatory reaction or
apparent pathological alteration in the Leydig cells in any of the
slides examined from rats administered either VAP or OXC.
Spermatogenetic cells and stages were evaluated, and quantitative
analysis was performed based on previous reports and guide-
lines.17–22 The absence of any prominent morphological abnor-
mality in our study does not correlate with the reduced testicular
weights in the VPA group. This contrasts with Røste et al.’s study,9
which showed atrophic tubules and spermatogenetic arrest at the
prophase of the ﬁrst meiosis correlated with a decrease in testis
weights. Although the decrease in testis weight was not statisti-
cally signiﬁcant, it is likely that declining numbers of spermatogo-
nia, pachytene spermatocytes and round spermatocytes and
minimal changes in cell diameters played a role in this decrease.
In addition, increased apoptosis and p53 and decreased TGF-b1
staining may indicate deﬁnite levels of cell arrest and support
decreases in the testis tissue. To the best of our knowledge, the
literature contains no studies on the histopathological change in
the testis tissue caused by OXC. This study demonstrates that in
contrast to the negative effects in female rat ovarian tissues caused
by OXC,25,26 it does not lead to prominent changes in spermato-
genetic cells and stages in male rats.
Apoptosis normally occurs in the ﬁrst pubertal spermatogenetic
wave in order to maintain a physiological quantity of germ
cells,27,28 VPA has been shown to have proapoptotic effects on
human and rat granulosa cells by increasing caspase-3 and positive
staining using the TUNEL method.25,29 Bielecka and Obuchowicz30
also noted the studies demonstrating its apoptosis-promoting
effect and suggested that the ultimate effect depends on the drug
dose and experimentalmodel.We observed, for the ﬁrst time in the
literature, high apoptotic indices in the VPA group using the TUNEL
method in testis tissue, which should properly be interpreted in
view of the above-mentioned dual effects of VPA on apoptotic
pathways and requires further experimentation.
Three more recent studies have reported that OXC causes
edema and apoptosis in retinal ganglion cells, and ovarian and
endometrial tissues.25,26,31 OXC gives rise to swelling and edema in
some cells, leading to impairment and subsequent apoptosis and
cell death in cell organelles. This particularly occurs in more aged
cells.25,26 In contrast, we observed neither edema nor prominent
apoptosis in the Sertoli cells, spermatocytes or spermatid cells of
the rats administered OXC. We cannot account for this with the
data available. Arau´jo et al.32 showed that, as demonstrated, OXC
causes edema of the hippocampal neurons due to a decrease in
mitochondrial membrane potential. The absence of edema and
apoptosis in Sertoli cells, spermatocytes and spermatid cells may
stem from OXC treatment causing no signiﬁcant change in these
cells’ mitochondrial membrane potentials, in contrast to other
cells.his is strong in the control group (A), weak in the VPA group (B) andmoderate in the
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TGF-b1 stainings. It had previously been shown that enhanced p53
protein levels lead to cell cycle arrest, and high levels can trigger
apoptosis in response to stress or DNA damage.33,34 As a potent
inducer of apoptosis and regulator of cell growth, p53 is found in
high concentrations in the testis.35 The fact that in our study,
intensity of labeling, HSCORE, and the percentages of follicles with
moderate to strong labeling intensity for P53 increased in the VPA
group alongwith high apoptotic cell counts supports this view.We
also performed immunostaining for TGF-b1. This is known to pay a
regulatory role in the hormonal control of adrenals in both sexes.
TGF-b1 is expressed in spermatogonia, spermatocytes, and round
but not elongated spermatids of both 21-day-old and adult Wistar
rats.36 Teerds and Dorrington36 suggested that TGF-bs either
promote the differentiation of germ cells in an autocrine fashion or
else maintain the necessary communication with adjacent Sertoli
cells. TGF-b1 has been shown to speciﬁcally stimulate and increase
the DNA synthesis level of preleptotene spermatocytes in the
spermatogenic stage VIIa.37 Fertility in TGF-b1 null mutant mice
has been demonstrated to be severely impaired.38 Since we
observed a low TGF-b1 expression in our study, it is possible that
fertility may have been affected by treatment with VPA. However,
these results for TGF-b1 cannot easily be applied to humans, as
TGF-b1 has not been detected in human seminiferous tubular
cells.39
We did not investigate the hormonal effects of VPA. We cannot
therefore say that these VPA-associated changed in the testis tissue
are related to effects directly established by VPA at tissue level, and
some of these effects may be ascribed to VPA-associated hormonal
changes.
In conclusion, our study shows negative trophic effects of VPA
on the testis but none caused by OXC. Quantitative morphological
analysis of the spermatogenesis revealed no signiﬁcant difference
from the control group in either the VPA or OXC groups. Apoptotic
index was elevated in the VPA group, with reduced TGF-b1
expression. These ﬁndings are partially in agreementwith previous
studies on the reproductive toxicity of VPA. We observed no
serious abnormalities in the OXC group, and this is to our
knowledge the ﬁrst report on the effects of OXC on the rat testis.
Our ﬁndings should now be tested using different methods and
larger numbers of subjects in future studies.
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